Involvement of SK3 Calcium Channel in Taxane Neuropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-06

Study Completion Date

2020-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Taxane neuropathy is a common and long-term side effect of long-term morbidity in patients surviving cancer. No preventive or symptomatic treatment has been shown to be effective. Its pathophysiology is poorly known and probably multifactorial. A possible mechanism would be mediated by the activation of the SK3 calcium channel: a retrospective study carried out at the University Hospital of Tours (Carina RUA) found a significant association between the number of CAG triplets in the KCNN3 gene coding for the SK3 channel and the appearance of a taxane neuropathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy

NCT02831114

Peripheral Neuropathy

COMPLETED NA

Effects of an Exercise Intervention on Taxane-induced Peripheral Neuropathy in Breast Cancer Survivors

NCT05641571

CIPN - Chemotherapy-Induced Peripheral Neuropathy

UNKNOWN NA

Exercise and Nutrition Interventions During Chemotherapy K07

NCT03858153

Neuropathy;Peripheral

COMPLETED PHASE2

Acupuncture for CIPN in Breast Cancer Patients

NCT02615678

Sensation Disorders Neuropathy

COMPLETED NA

Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies

NCT03854864

Chemotherapy-induced Peripheral Neuropathy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer, will be offered the study.

The mode of administration of chemotherapy and the usual follow-up will not be modified by the protocol The determination of the SK3 status will be made from an additional tube collected during a collection as part of the treatment at the first arrival in a day hospital (no more blood tests). Blood sample of 7mL. Shipments and analyzes of samples in Tours in the pharmacogenetics laboratory under the responsibility of Dr. BARIN-LE GUELLEC.

This study is non-invasive, without impact on the therapeutic management. The result of the polymorphism of SK3 will not be indicated in the record, so as not to influence the follow-up of the treatment and to allow an evaluation of the occurrence of peripheral neuropathy in blindness of the number of repetitions of the CAG triplet of the KCNN3 gene.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Chemotherapy-induced Peripheral Neuropathy Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast or prostate cancer

Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer

Blood samples

Intervention Type OTHER

Blood samples before the introduction of chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

Blood samples before the introduction of chemotherapy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Breast Group

* Age ≥ 18 years
* Breast cancer
* Chemotherapy with paclitaxel or docetaxel
* Adjuvant or neoadjuvant chemotherapy in localized cancer or first-line treatment in metastatic cancer
* Signed informed consent

Prostate Group

* Age ≥ 18 years
* Metastatic prostate cancer
* Chemotherapy with docetaxel in 1st line
* Signed informed consent

Exclusion Criteria

* Anteriority or concomitance of another chemotherapy provider of neuropathy (platinum salts)
* Another possible cause of neuropathy: diabetes, alcoholism, vitamin B9 / B12 deficiency, neurodegenerative disease, Raynaud's syndrome

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No